Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269
Open Access
- 6 December 2019
- journal article
- research article
- Published by Informa UK Limited in Human Vaccines & Immunotherapeutics
- Vol. 16 (4), 945-948
- https://doi.org/10.1080/21645515.2019.1688039
Abstract
The Meningococcal Antigen Typing System (MATS) has been developed as an hSBA surrogate to evaluate potential coverage afforded by the 4-component meningococcal serogroup B vaccine (4CMenB: Bexsero, GSK). We investigated whether the lower value of MATS coverage among invasive Meningococcus serogroup B clonal complex 269 strains from the United Kingdom (53% in 2014–2015 versus 73% in 2007–2008) reflected the lower bactericidal activity of the vaccine against these isolates. A total of 34 MATS-negative strains (31 were cc269 or closely related) were tested against pooled sera from 32 or 72 4CMenB-vaccinated infants in a serum bactericidal antibody assay in presence of human complement (hSBA). All infants had received four 4CMenB doses in the first 2 y of life. Baseline sera comprised 180 pooled samples from healthy-unvaccinated 2-month-old infants. Twenty of the 34 (59%) MATS-negative strains were killed in hSBA with titers ≥4 by pooled sera from vaccinated infants. There were 13/34 strains with hSBA titers ≥4 and at least a 4-fold rise in titer with respect to pooled baseline sera, and 10/34 with hSBA titers ≥8 and at least a 4-fold rise in titer with respect to baseline. These data confirm MATS as a conservative estimate for predicting strain coverage by 4CMenB.Keywords
Funding Information
- GlaxoSmithKline Biologicals SA
This publication has 15 references indexed in Scilit:
- Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopesScientific Reports, 2018
- Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007–08 and 2014–15: a qualitative and quantitative assessmentThe Lancet Infectious Diseases, 2017
- Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort studyThe Lancet, 2016
- Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of AgeThe Pediatric Infectious Disease Journal, 2016
- Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverageVaccine, 2013
- Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigenVaccine, 2011
- Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccinesProceedings of the National Academy of Sciences of the United States of America, 2010
- Interlaboratory Standardization of the Measurement of Serum Bactericidal Activity by Using Human Complement against Meningococcal Serogroup B, Strain 44/76-SL, before and after Vaccination with the Norwegian MenBvac Outer Membrane Vesicle VaccineClinical and Vaccine Immunology, 2005
- HUMAN IMMUNITY TO THE MENINGOCOCCUSThe Journal of Experimental Medicine, 1969
- HUMAN IMMUNITY TO THE MENINGOCOCCUSThe Journal of Experimental Medicine, 1969